The vaccine, called mFlusiva, was approved for older adults. In trials, it was found to be about 27% more effective than a ...
As Cosmo’s assistant beauty editor, I spend hours each week searching for new nail trends and inspo. I’m always chatting with nail techs, stalking celebrity manicures, and scrolling my feeds for new ...
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and ...
The cases add to a web of high-stakes patent lawsuits filed by biotech companies against Pfizer and Moderna over the mRNA technology used in their COVID vaccines. Spokespeople for Pfizer and Moderna ...
As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new front to challenge the companies’ blockbuster COVID-19 vaccines. In ...
Days after buckled columns at the Pfizer building conversion sparked concerns that the project was in danger of collapse, key parties at the property are facing scrutiny over past violations. A ...
MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat. Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits ...
On June 16, 2026, U.S. District Judge Gregory B. Williams of the United States District Court for the District of Delaware issued a memorandum order resolving three partial motions to dismiss ...
For this story, Boodman obtained email chains between Pfizer and health officials and conducted interviews with 10 state health departments, eight local health agencies, six health system pharmacists, ...
You’ll have city and wilderness, ocean and mountain, refinement and raw beauty. 1: Elegant Buenos Aires, European in spirit, Latin in character (stay: Palacio Duhau). 2: Patagonia Azul, a protected ...
Pfizer PFE reported 5% top-line growth but an 18% decline in adjusted diluted EPS, mostly due to royalty expenses weighing on its gross margin. Management maintained its full-year guidance for $59.5 ...
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results